US 12,281,110 B2
Processes for preparing an FGFR inhibitor
Jiang Zhu, San Ramon, CA (US); and Mohammad Masjedizadeh, San Jose, CA (US)
Assigned to Principia Biopharma, Inc., Bridgewater, NJ (US)
Filed by Principia Biopharma, Inc., South San Francisco, CA (US)
Filed on Jan. 22, 2021, as Appl. No. 17/155,726.
Application 17/155,726 is a division of application No. 16/745,418, filed on Jan. 17, 2020, granted, now 10,899,760.
Application 16/745,418 is a continuation of application No. 15/748,212, granted, now 10,538,518, issued on Jan. 21, 2020, previously published as PCT/US2016/046304, filed on Aug. 10, 2016.
Claims priority of provisional application 62/203,498, filed on Aug. 11, 2015.
Prior Publication US 2021/0147417 A1, May 20, 2021
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01); C07B 35/02 (2006.01); C07B 35/06 (2006.01); C07B 39/00 (2006.01); C07B 43/04 (2006.01); C07B 43/06 (2006.01); C07B 45/04 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01); C07B 35/02 (2013.01); C07B 35/06 (2013.01); C07B 39/00 (2013.01); C07B 43/04 (2013.01); C07B 43/06 (2013.01); C07B 45/04 (2013.01); C07B 2200/13 (2013.01)] 19 Claims
 
1. A crystalline free base of a compound of formula:

OG Complex Work Unit Chemistry